Core Viewpoint - A class action lawsuit has been filed against Allarity Therapeutics, Inc. for allegedly making materially false and misleading statements regarding its business and operations during the class period from May 17, 2022, to July 19, 2024 [1][3]. Summary by Sections Lawsuit Details - The lawsuit is filed in the United States District Court for the Southern District of New York on behalf of all individuals and entities who purchased Allarity securities during the specified class period [1]. - Investors have until November 12, 2024, to apply to be appointed as lead plaintiff in the lawsuit [1]. Allegations Against the Company - The complaint alleges that Allarity and its former officers overstated the regulatory prospects of the Dovitinib NDA [3]. - It is claimed that the company engaged in illegal and improper conduct related to the Dovitinib NDA and Dovitinib-DRP PMA [3]. - The misconduct allegedly increased the risk of regulatory scrutiny and enforcement actions, leading to potential legal, monetary, and reputational harm [3]. - Following the announcement of an investigation into wrongdoing, the company reportedly downplayed the likelihood of enforcement actions resulting from the investigation [3]. - As a result, the company's public statements were deemed materially false and misleading throughout the class period [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Allarity Therapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on November 12, 2024 [1]. Group 1: Class Action Details - Investors who bought Allarity securities between May 17, 2022, and July 19, 2024, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the Court by November 12, 2024 [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. Group 3: Case Allegations - The lawsuit alleges that Allarity and its former officers made false and misleading statements regarding the regulatory prospects of their drug candidate Dovitinib, which treats renal cell carcinoma [5]. - It is claimed that the defendants engaged in improper conduct related to the Dovitinib new drug application and premarket approval application, leading to increased regulatory scrutiny and potential legal repercussions [5]. - Following the announcement of an investigation into Allarity's conduct, the company allegedly downplayed the likelihood of enforcement actions, resulting in materially false public statements [5].

NEW YORK, Nov. 02, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline. SO WHAT: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

NEW YORK, Nov. 1, 2024 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the "Class Period"), of the important November 12, 2024 lead plaintiff deadline.So what: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.Wh ...

Core Points - Rosen Law Firm is reminding purchasers of Allarity Therapeutics, Inc. securities about the lead plaintiff deadline of November 12, 2024, for a class action lawsuit [1] - Investors who purchased Allarity securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the firm [3] Case Details - The lawsuit alleges that Allarity and its former officers made false and misleading statements regarding the regulatory prospects of Dovitinib, a drug candidate for renal cell carcinoma [5] - It is claimed that Allarity engaged in improper conduct related to the Dovitinib new drug application and premarket approval application, leading to increased regulatory scrutiny and potential legal repercussions [5] - The lawsuit asserts that Allarity downplayed the likelihood of enforcement actions following an investigation into its conduct, resulting in materially false public statements [5]

European Patent Office to grant a patent for DRP® companion diagnostic for Allarity’s stenoparib cancer therapy Patent applications for the Stenoparib DRP® are also pending in the US, Japan, China, Australia, and India Boston (October 22, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selection technology, today announced that the Eur ...

NEW YORK, Oct. 20, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline. SO WHAT: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Allarity Therapeutics, Inc. due to allegations of violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action by November 12, 2024 [2][3]. Company Overview - Allarity Therapeutics, Inc. is facing scrutiny for allegedly making false and misleading statements regarding its business operations and compliance policies, particularly related to the Dovitinib NDA [3]. - The company has experienced significant leadership changes, including the appointment of interim executives and the termination of its CEO and CFO [4][5][7]. Financial Impact - Following the announcement of leadership changes, Allarity's stock price fell by 19.02% to $1.32 per share on June 30, 2022 [5]. - The stock price further declined by 3.688% to $1.175 per share on August 2, 2022, after the company announced a strategic refocus away from Dovitinib as a monotherapy [6]. - On February 6, 2023, the stock price dropped by 3.8% to $0.228 per share after the company disclosed an SEC investigation [7]. - The stock price fell by 13.37% to $0.486 per share on December 11, 2023, following the termination of the CEO [8]. - On July 22, 2024, the stock price decreased by 2.38% to $0.164 per share after the company received a Wells Notice from the SEC [8]. Legal Proceedings - The class action lawsuit alleges that Allarity and its executives engaged in misconduct that led to increased regulatory scrutiny and potential enforcement actions [3]. - The firm encourages investors who suffered losses exceeding $50,000 between May 17, 2022, and July 19, 2024, to discuss their legal options [1][2].

NEW YORK, Oct. 13, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline. SO WHAT: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Allarity Therapeutics, Inc. securities between May 17, 2022, and July 19, 2024, of the upcoming lead plaintiff deadline on November 12, 2024, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Allarity securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 12, 2024 [2]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [3]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [3]. Group 3: Case Allegations - The lawsuit alleges that Allarity made false and misleading statements regarding its drug candidate Dovitinib, overstating its regulatory prospects and engaging in improper conduct related to its new drug application [4]. - The misconduct allegedly led to increased risks of regulatory scrutiny and enforcement actions, resulting in significant legal and reputational harm to Allarity [4]. - Following the announcement of an investigation into Allarity's conduct, the company downplayed the likelihood of enforcement actions, which the lawsuit claims caused investor damages when the truth was revealed [4].